News

This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, highlighting its focus on serving the best interests of their consumers.

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

Much of the association between trauma and suicide risk among university students can be explained by shame, a new study finds.

Here’s what you missed this week on Managed Healthcare Executive.

A new bipartisan bill aims to cancel the 2.83% cut to Medicare payments to physician practices.

As a non-opioid drug, Journavx can assist patients effectively and without showing signs of being addictive.

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by the success of Evernorth Health Services, new client acquisitions and growth in the specialty drug space.

After several days of worry that the global AIDS program might come to abrupt end, Secretary of State Marco Rubio issued a humanitarian waiver that appears to have restored funding.

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt on the safety and efficacy of vaccines.

In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.

The survey also showed that high drug costs and artificial intelligence are topmost among the respondent’s concerns.

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer experience and deliver better health outcomes

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending have not affected the public’s feelings on these programs.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research shows.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.

Here’s what you missed this week on Managed Healthcare Executive.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who weigh at least 13 pounds.

Wendy Watson takes over Kaiser Foundation Health Plan and Hospitals of the Northwest, and Corwin N. Harper becomes president of Kaiser Foundation Health Plan of Georgia.

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.

TriVerity focuses on whether the patient has an infection and how severely ill they are likely to become.

Ways workplaces and insurance companies have begun to support menopausal women, according to Jenifer Allbright, Director of G&A Beneficial at G&A Partners.

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22, 2025.

First discovered in the Netherlands roughly 24 years ago, HMPV belongs to the same viral family as RSV.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

The development of avian influenza vaccines is the main priority amid rising cases in the United States.

Health policy leaders say withdrawing from the WHO is a global health crisis in the making.